Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.

@article{Kopylov2014AdalimumabMV,
  title={Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.},
  author={Uri Kopylov and Talal Al-Taweel and Mohammad Ali Yaghoobi and B{\'e}n{\'e}dicte Nauche and Alain Bitton and Peter L Lakatos and Shomron Ben-Horin and Waqqas Afif and Ernest G Seidman},
  journal={Journal of Crohn's & colitis},
  year={2014},
  volume={8 12},
  pages={1632-41}
}
BACKGROUND AND AIMS Combination therapy with infliximab and azathioprine has been shown to be superior to either treatment alone in Crohn's disease (CD). However, the benefit of combining adalimumab with an immunomodulator remains controversial. The aim of this study was to compare the efficacy of adalimumab monotherapy with combination therapy for induction and maintenance of response and remission in CD using a meta-analysis of the current literature. METHODS We performed a systematic… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

Second Korean guidelines for the management of Crohn's disease

Intestinal research • 2017
View 3 Excerpts
Highly Influenced

Combination therapy for inflammatory bowel disease

World journal of gastrointestinal pharmacology and therapeutics • 2017

References

Publications referenced by this paper.
Showing 1-10 of 51 references

Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-tumor necrosis factor-α agents.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2013

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association • 2013

Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients

Y Mazor, U Kopylov, D Ben Hur
2013

Similar Papers

Loading similar papers…